Related Experiment Video
Updated: May 24, 2026
10:41
Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity
Published on: February 17, 2017
Microbial heparin/heparan sulphate lyases: potential and applications
C K M Tripathi1, Jaspreet Banga, Vikas Mishra
1CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India. ckm_tripathi@cdri.res.in
Applied Microbiology and Biotechnology
|March 7, 2012
Summary
Microbial heparinases degrade heparin/heparan sulphate glycosaminoglycans (HSGAGs) into biologically active oligosaccharides. These compounds have significant therapeutic potential for anticoagulation, cancer, and angiogenesis.
Area of Science:
- Biochemistry
- Enzymology
- Glycobiology
Background:
- Heparin/heparan sulphate glycosaminoglycans (HSGAGs) are crucial in cellular functions, including blood coagulation and inflammation.
- Cancer progression involves thrombosis, highlighting the coagulation system's role in angiogenesis and metastasis.
Purpose of the Study:
- To review the degradation of HSGAGs by microbial heparin/heparan sulphate lyases.
- To explore the therapeutic potential of generated oligosaccharides for various clinical applications.
Main Methods:
- Cataloguing microbial heparin/heparan sulphate lyases and their enzymatic activity.
- Reviewing studies on the generation and biological activity of oligosaccharides derived from HSGAGs.
Main Results:
- Heparinases specifically cleave HSGAGs, producing biologically active oligosaccharides.
- These oligosaccharides exhibit potential in anticoagulation, cancer therapy, and controlling angiogenesis and metastasis.
- Enzyme source and preparation methods influence oligosaccharide bioavailability and pharmacokinetics.
Conclusions:
- Microbial heparinases offer a pathway to generate novel oligosaccharides with significant therapeutic applications.
- Further research into enzyme-specific or dual-role oligosaccharides could lead to new pharmaceutical compounds.
